Ensuring Compatibility for GLP-1-based Drugs
The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance delivery efficiency and reduce costs in obesity treatment.
- Publisher
- Stevanato Group
- Published
- Length
- 10 pages
- File
- 478 KB PDF
Download the full 10-page PDF
Free · 478 KB · Instant access after email
This white paper highlights the growing demand for GLP-1-based drugs and the importance of compatible delivery systems. Key findings include:
- Global spending on weight management drugs projected to exceed USD 70 billion by 2028.
- GLP-1 agonists, initially for diabetes, now show efficacy comparable to bariatric surgery.
- Ready-to-fill cartridges streamline the filling process, reducing costs and complexity.
- Stevanato Group's EZ-fill® platform enhances compatibility and minimizes quality risks.
- Stability studies indicate consistent performance of Nexa® EZ-fill® cartridges with GLP-1 formulations.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
More whitepapers like this
Strategies to Enhance Recruitment of Female Participants to Cardiovascular Research
This consensus document outlines strategies to increase female representation in cardiovascular clinical trials, addressing significant under-representation of women.
British Society of Gastroenterology Guidelines on Inflammatory Bowel Disease in Adults: 2025
The updated BSG guidelines emphasize the necessity of ileocolonoscopy for IBD diagnosis and advocate for immunomodulators in all patients.
🔒 From Automotive to MedTech: Proven Software Development Practices
This whitepaper outlines how MedTech can leverage automotive software development practices to enhance compliance and accelerate innovation cycles.